Cargando…

Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease

To assess plasma phosphorylated tau181 (p-tau181) as a progression biomarker in Alzheimer’s disease (AD), we examined longitudinal plasma p-tau181 of 1184 participants (403 cognitively normal (CN), 560 patients with mild cognitive impairment (MCI), and 221 with AD dementia) from Alzheimer’s Disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shi-Dong, Huang, Yu-Yuan, Shen, Xue-Ning, Guo, Yu, Tan, Lan, Dong, Qiang, Yu, Jin-Tai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197760/ https://www.ncbi.nlm.nih.gov/pubmed/34120152 http://dx.doi.org/10.1038/s41398-021-01476-7

Ejemplares similares

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
por: Thijssen, Elisabeth H., et al.
Publicado: (2020)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
por: Ding, Xulong, et al.
Publicado: (2021)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
por: Qin, Wei, et al.
Publicado: (2022)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Plasma Phosphorylated-tau181 Is a Predictor of Post-stroke Cognitive Impairment: A Longitudinal Study
por: Huang, Li-Kai, et al.
Publicado: (2022)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
por: Tsantzali, Ioanna, et al.
Publicado: (2022)

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Erratum to: Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Publicado: (2021)

Plasma phosphorylated tau181 predicts cognitive and functional decline
por: Tropea, Thomas F., et al.
Publicado: (2022)

Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET
por: Guo, Yu, et al.
Publicado: (2021)

A Longitudinal Study of Plasma pTau181 in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease
por: Thomas, Alan J., et al.
Publicado: (2022)

Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study
por: Wang, Yan-Li, et al.
Publicado: (2021)

Association of APOE ɛ4 and Plasma p-tau181 with Preclinical Alzheimer’s Disease and Longitudinal Change in Hippocampus Function
por: Salami, Alireza, et al.
Publicado: (2022)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

Plasma α‐synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson’s disease
por: Ren, Jingru, et al.
Publicado: (2022)

Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment
por: Chen, Jingshan, et al.
Publicado: (2023)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
por: Marksteiner, Josef, et al.
Publicado: (2022)

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
por: Wilson, Edward N., et al.
Publicado: (2022)

Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression
por: Tsiknia, Amaryllis A., et al.
Publicado: (2022)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease
por: Yu, Chao-Chao, et al.
Publicado: (2019)

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
por: De Meyer, Steffi, et al.
Publicado: (2022)

Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders
por: Tzartos, John S., et al.
Publicado: (2022)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction
por: Thanapornsangsuth, Poosanu, et al.
Publicado: (2022)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer’s Disease
por: Kalia, Vrinda, et al.
Publicado: (2023)

Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition
por: Rauchmann, Boris Stephan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u7d8ptljvb386m3r1k75iee91c